Seelos Therapeutics (NASDAQ:SEEL) acquired an exclusive license to a family of peptide inhibitors that target the aggregation of alpha-synuclein, a protein implicated in Parkinson’s disease (PD).
Seelos will develop the technology, created by researchers at the University of California, Los Angeles, in a new program called SLS-007. The company plans to evaluate the potential for in vivo delivery of SLS-007 in a mouse model of PD and determine the drug’s pharmacokinetic and pharmacodynamic parameters.
Initially, Seelos plans to evaluate SLS-007’s potential to treat PD but intends to evaluate the potential clinical approach in other CNS disorders.
